Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pulmonx Corporation SEC filings document the company’s medical technology business, Nasdaq-listed common stock and formal disclosures around operating results, governance, compensation and capital structure. Recent 8-K filings furnish quarterly and annual financial results for the Zephyr Valve-focused lung disease treatment business, including revenue by geography, gross margin, restructuring activity and related management commentary.
The filing record also includes material agreement disclosures for a senior secured term loan facility, proxy materials covering annual meeting proposals, director elections, auditor ratification and executive compensation votes, and 8-K disclosures tied to leadership transitions, separation arrangements and inducement equity awards.
Pulmonx Corporation reported the results of its 2026 annual meeting of stockholders. A total of 32,645,270 shares were present or represented by proxy, representing approximately 77.29% of the 42,237,203 shares outstanding and entitled to vote as of April 7, 2026.
Stockholders elected three Class III directors — Thomas W. Burns, Georgia Garinois-Melenikiotou, and Dana G. Mead, Jr. — to serve until the 2029 annual meeting and until their successors are elected and qualified.
Stockholders also ratified the appointment of BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, and approved, on a non-binding advisory basis, the company’s executive compensation as described in the proxy statement.
Pulmonx Corp Chief Science & Techn. Officer Radhakrishnan Srikanth reported routine share sales tied to tax withholding. On June 1, 2026, he sold a total of 14,497 shares of Pulmonx common stock in four open-market transactions at $1.54 per share. According to the footnotes, each sale was made solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026.
Pulmonx Corp General Counsel David Aaron Lehman reported the sale of a total of 14,594 shares of Pulmonx common stock on June 1, 2026 at a price of $1.54 per share, executed in four separate transactions. According to the footnotes, all of these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on March 1, 2023, March 1, 2024, March 3, 2025, and March 2, 2026, making the activity compensation- and tax-related rather than a discretionary reduction of his investment position.
Pulmonx Corp’s Chief Commercial Officer Geoffrey Beran Rose reported multiple small sales of Pulmonx common stock. In total, he sold 8,023 shares at $1.54 per share on June 1, 2026.
According to the footnotes, each sale was made solely to cover tax withholding obligations tied to vesting Restricted Stock Units granted in 2023, 2024, 2025, and 2026. After these transactions, he continues to hold 463,956 Pulmonx shares directly, indicating these are routine tax-related dispositions rather than a broad reduction of his position.
Pulmonx Corp President and CEO Glendon E. French III reported tax-related share sales. On June 1–2, 2026, he sold a total of 56,149 shares of Common Stock at prices around $1.54–$1.57 per share. A footnote explains these shares were sold to cover tax withholding obligations tied to vesting of Restricted Stock Units granted on March 1, 2023, making them compensation-related rather than discretionary trades. After the transactions, he held 1,178,162 shares directly, and a family trust held an additional 918,198 shares indirectly.
Pulmonx Corporation reported Q1 2026 results showing continued growth investment and operating losses. Revenue was $20.6 million versus $22.5 million a year earlier, with gross margin improving to 77.9%. The company posted a net loss of $13.7 million, or $0.33 per share, and an accumulated deficit of $535.2 million.
Pulmonx ended the quarter with $61.6 million in cash and cash equivalents and 42.2 million shares outstanding. It refinanced its prior CIBC facility with a new $40.0 million senior secured term loan from Perceptive, maturing in 2031 and partly bearing paid-in-kind interest, and issued related common stock warrants.
Pulmonx Corporation reported first-quarter 2026 results with lower revenue but improved margins and a slightly smaller loss. Revenue was $20.6 million, down 9% from $22.5 million a year earlier, with U.S. revenue of $13.3 million and international revenue of $7.3 million. International sales were hurt by a lack of sales into China while the company awaits renewal of its registration certificate; excluding China, international revenue grew 22%.
Gross profit was $16.0 million and gross margin improved to 78% from 73% in 2025. Operating expenses fell 6% to $29.0 million. Net loss narrowed to $13.7 million, or $0.33 per share, from $14.4 million, or $0.36 per share. Adjusted EBITDA loss was $8.5 million, and cash and cash equivalents totaled $61.6 million as of March 31, 2026.
Pulmonx reaffirmed its 2026 outlook, continuing to expect full-year revenue of $90–$92 million, gross margin of about 75%, and total operating expenses of $113–$115 million, including roughly $19 million of stock-based compensation. Management highlighted refreshed U.S. commercial strategies, a fully staffed global sales organization, and a recently refinanced 5-year interest-only credit facility maturing in 2031.
Pulmonx Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on June 4, 2026. Holders of 42,237,203 shares of common stock as of April 7, 2026 can attend online and vote on three items: electing three Class III directors, ratifying BDO USA as independent auditor for 2026, and approving a non-binding advisory “say‑on‑pay” vote on executive compensation.
The proxy describes a majority‑independent, staggered board with an independent chair and standard audit, compensation, and nominating committees. It highlights an insider trading and hedging policy, stock ownership guidelines, and a clawback policy. Executive pay mixes salary, annual bonuses and equity, including newly introduced performance stock units. For 2025, the corporate bonus plan paid out 20.6% of target after revenue fell below threshold while Adjusted EBITDA and limited strategic goals were partly achieved.
The Vanguard Group filed an amended Schedule 13G/A reporting that it beneficially owns 0 shares of Pulmonx Corp Common Stock (CUSIP 745848101). The filing states this follows an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, which resulted in certain Vanguard subsidiaries reporting ownership separately. The filing lists the filer address as 100 Vanguard Blvd., Malvern, PA and is signed by Ashley Grim on 03/27/2026.